January 7, 2019 | Lao Tribune

Daily Archives January 7, 2019

DXB Welcomes Billionth Passenger

DUBAI, United Arab Emirates, Jan. 07, 2019 (GLOBE NEWSWIRE) — Following the official announcement earlier today from HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President & Prime Minister of the UAE and Ruler of Dubai, Dubai Airports and representatives from across the aviation sector and the emirate of Dubai gave the airport’s billionth warm […]Read More

Checkpoint Therapeutics Initiates Registrational Development Programs ...

Ongoing endometrial and colorectal cancer cohorts intended to support BLA submissions NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that the ongoing multi-center clinical trial of […]Read More

Favored Tech Previews Groundbreaking Electronic Coating Tech at CES19

Patented Technology Makes Cell Phones Virtually Water Proof, Offers Comprehensive Protective Nano Coating for the Latest Electronic Devices LAS VEGAS, Jan. 07, 2019 (GLOBE NEWSWIRE) — Favored Tech, a leading provider for the next generation of multi-functional Nano Protection technology for an ever-growing world of electronic devices, today previewed its revolutionary coating technology at CES19. […]Read More

Fertin Pharma Acquires Tab Labs – Provides the Combined Group a ...

VEJLE, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) — Fertin Pharma A/S (“Fertin Pharma”) has signed and closed the acquisition of Tab Labs Inc. (“Tab Labs”), a leader in compressed gum and mints / lozenges and one of the largest contracts tableting companies in North America servicing customers within Nutraceuticals as well as Confectionery. Headquartered in […]Read More

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in ...

Demonstrated statistically significant improvement in MADRS scores compared to active comparator (p<0.001 on primary endpoint) Rapid improvement in depressive symptoms demonstrating statistically significant superiority over active comparator within the first week (p=0.045 on CGI-I) Improvement with AXS-05 versus active comparator seen on multiple secondary endpoints, including remission in 47% of AXS-05 patients versus 16% of […]Read More